33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Follows, G.; Burke, J. M.; Grosicki, S.; Chen, C.; Sanna, A.; Roeker, L. E.; Yi, S.; Munir, T.; de la Cruz, F.; Ferrant, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent
    Meeting Abstract

    Kumar, S.; Bachier, C. R.; Cavo, M.; Corradini, P.; Delforge, M.; Janowski, W.; Lesokhin, A. M.; Mina, R.; Paris, L.; Rosiñol, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Eyre, T. A.; Thompson, P.; Wierda, W. G.; Šimkovič, M.; Grosicki, S.; Jurczak, W.; Wang, Y.; Móciková, H.; Zinzani, P. L.; Tam, C. S. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial)
    Meeting Abstract

    Berdeja, J. G.; Martin, T. G.; Rossi, A.; Essell, J. H.; Siegel, D. S. D.; Mailankody, S.; Saini, N.; Holmes, H.; Dhakal, B.; Gasparetto, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2
    Meeting Abstract

    Sehn, L. H.; Chamuleau, M.; Lenz, G.; Clausen, M.; Haioun, C.; Izutsu, K.; Davies, A. J. J.; Zhu, J.; Oki, T.; Szafer-Glusman, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer
    Meeting Abstract

    Abdelhamid Ahmed, A. H.; Russell, M. D.; Kyriazidis, N.; Silver Karcioglu, A.; Sherman, E. J.; Ho, A. L.; Fagin, J. A.; Wong, R. J.; Busaidy, N. L.; Zafereo, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Atallah, E. L.; Mauro, M. J.; Sasaki, K.; Levy, M. Y.; Koller, P. B.; Sadek, I.; Yang, D.; Ruckel-Kumar, J.; Khan, M. H.; Cortes, J. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
    Meeting Abstract

    Smith, C. C.; Vachhani, P.; Garcia-Manero, G.; Grieselhuber, N. R.; Guru Murthy, G. S.; Bhatia, A.; Arora, J.; Izadi, H.; Fiorino, A.; Rampal, R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Meeting Abstract

    Ho, A. L.; Adkins, D.; Lorch, J. H.; Thomas, J. S.; Grewal, J. S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M. J.; Rampal, R.; Bose, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save